SOURCE: BioSig Technologies Inc

BioSig Technologies Inc

January 07, 2015 09:00 ET

BioSig Files International Patent Application - Systems and Methods for Evaluation of Electrophysiology Systems

LOS ANGELES, CA--(Marketwired - Jan 7, 2015) - BioSig Technologies (OTCQB: BSGM), a medical device company that has developed and is preparing to commercialize its proprietary PURE EP™ technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures, announced today it has filed a Patent Cooperation Treaty (PCT) application for technology related to the method for evaluating the PURE EP System and existing EP recording systems. 

Gregory D. Cash, BioSig's Chief Executive Officer, said, "Presently, anatomical markers are the cornerstone for arrhythmia ablation strategies. As arrhythmia recurrence is high, additional endpoints of cardiac tissue nonexcitability based on signal morphology are necessary. The PURE EP System's technology has been designed to preserve signal morphology. Our patent application allows objective evaluation of the capabilities of the PURE EP System as compared to existing EP information and recording devices."

About BioSig Technologies
BioSig is a medical device company that has developed a proprietary technology platform designed to improve the $3 billion electrophysiology (EP) marketplace that analysts forecast growing at 12.1 percent(1), ( Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig is preparing to commercialize its PURE EP System.

PURE EP is a next-generation surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing guidance in identifying ablation targets -- areas of tissue to destroy that otherwise create a heart rhythm disturbance (arrhythmia). 

BioSig intends to seek FDA 510(k) approval for the PURE EP System. The Company has already achieved proof of concept validation through UCLA EP & Animal Labs, and is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including TCAI, UCLA and Mayo Clinic.

Forward-Looking Statements
This release includes forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, regulatory approvals, competition and marketplace demand. More information, and BioSig risk factors, are set forth in its filings with the SEC. BioSig assumes no obligation to publicly update or revise its forward-looking statements.

(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Contact Information